Biotech | December 17, 2021
New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination
Effectiveness of Covaxin against the Omicron variant is currently being studied
Effectiveness of Covaxin against the Omicron variant is currently being studied
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
New bioinformatic workflow advances analysis capabilities for whole-exome assessment and interpretation
Subscribe To Our Newsletter & Stay Updated
